Global biomedical content represents critical data for pharmaceutical companies, healthcare and insurance providers and publishers. Such content cannot be easily handled by business applications because it is unstructured and varies across different
data sources. With speed and accuracy necessities in the medical field, organizations must find a way to overcome this barrier to understanding language.
A hybrid approach to artificial intelligence, combining the strengths of both natural language understanding (NLU) and machine learning (ML), provides an ideal solution that mimics the human-like comprehension of biomedical content such as clinical
trials, real-world data, medical reports, literature, and social media, to name a few.
This capability can help to accelerate drug discovery and development, innovate faster and increase access to healthcare. This session will start with a demonstration of hybrid NL capabilities which goes beyond entity extraction to relationship identification.
It will then be followed by a study on the importance of the human dimension when utilizing AI to combine ten years of clinical trial data with real-world data, literature, and social media data. The session will then conclude with key considerations
to win with AI and NLU in the gene therapy space.
In this webinar, you will learn:
- How NLU can accurately transform clinical trials data, real-world data and scientific literature into knowledge and insight.
- How to recognize the operational challenges that may stand in the way of your project’s success, to prevent data-driven projects from being derailed.
- What the key considerations are to winning with AI and NLP across therapeutic areas.
Data Science, Data Engineering, Clinical Analytics, Clinical Researchers, Scientists, CIOs, CTOs, Digital Marketing, Directors of Innovation and Strategy
Head of Healthcare and Life Sciences, North America Sales
Christophe Aubry leads business activities in specialized markets for expert.ai, the leading provider of AI-based Natural Language Understanding solutions. As a strategic technology leader focused on delivering solutions that solve customer pain points, Christophe has dedicated the last 20 years of his career to creating business value for clients worldwide. He helped his company establish its presence in North America, earning and consolidating the trust of major clients in media, publishing, life sciences, or government sectors. Christophe started his career as a Product Manager at IBM in the early stages of data and text mining. As a co-founder and Vice President Professional Services at TEMIS for more than 10 years, he molded talents to help them reach their highest potential while supervising customer deployments in all geographies and leading strategic service activities. His favorite quote is “A company’s employees are its greatest assets and your people are your product”. Christophe has a deep understanding and passion for AI technologies. He holds a Master’s Degree in Applied Mathematics and Computer Sciences.
Founder, Unconventional Innovation, Senior Director Digital Transformation
Dany is an engineer trained in biology with 20+ years of industry experience at biopharmaceutical companies GSK and Sanofi. In various global positions he supported R&D, clinical, manufacturing and regulatory submissions. He currently leads the implementation of several cognitive and other innovative technologies which builds on his earlier work in automation and the development of culture change platforms.
At Intergalactic Therapeutics, Mr. Hennemand is currently Chief Operating and Business Officer. Prior to his tenure at Intergalactic, Vincent was SVP Head of Strategy, Corporate and Business Development as well as Head of Immuno-Inflammation. In his prior tenure, Vincent worked at PureTech Health, the founding institution of Akili Therapeutic Labs as Vice President Strategy Corporate and Business Development across the portfolio companies. Vincent spent a decade in Pharma at Sanofi Genzyme during which he had the opportunity to hold several positions from R&D, General Management, Manufacturing and Corporate Venture (SGBV) where he was responsible for developing and managing new investment opportunities including Myokardia, Voyager Therapeutics, WarpDrive Bio and Portal Instruments. He holds an MSc in Engineering from Ecole Nationale Superieure Arts et Metiers in France, an MSc in Bioengineering from Georgia Tech, and an MBA from MIT where he received a Martin Trust Center Fellowship.
Expert.ai is the premier artificial intelligence platform for language understanding. Its unique hybrid approach to NL combines symbolic human-like comprehension and machine learning to transform language-intensive processes into practical knowledge,
providing the insight required to improve decision-making throughout organizations. By offering a full range of on-premise, private and public cloud offerings, expert.ai augments business operations, accelerates and scales data science capabilities
and simplifies AI adoption across a vast range of industries including Insurance, Banking & Finance, Publishing & Media, Defence & Intelligence, Life Science & Pharma, Oil Gas & Energy, and more. The expert.ai brand is
owned by Expert System (EXSY:MIL), that has cemented itself at the forefront of natural language solutions, and serves global businesses such as AXA XL, Lloyd's of London, Zurich Insurance Group, Generali, Bloomberg BNA, BNP Paribas, Rabobank,
Dow Jones, Gannett, IMF and EBSCO.
Cost: No Cost!